{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:05:53Z","timestamp":1792789553709,"version":"4.5.0"},"reference-count":40,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Idorsia Pharmaceuticals US Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Insomnia is the most prevalent sleep disorder, affecting millions worldwide and taking a heavy toll on patient health with significant social and economic impact. Even though there are multiple different types of insomnia medications and behavioral therapies, there are still many individuals for whom treatment remains ineffective. The objective of this retrospective study was to analyze the effectiveness of daridorexant in a cohort of chronic insomnia patients largely transitioned from GABA-A positive allosteric modulators (benzodiazepines, zolpidem or eszopiclone) or other frequently prescribed insomnia medications (including trazodone, atypical antipsychotics or tricyclic antidepressants). A total of 86 patients were treated in the course of ordinary practice and the primary analytic endpoint was the change in Insomnia Severity Index (ISI) score following \u2265 30 nights of treatment with daridorexant. Results from 80 of the 86 patients with full data (65% female, mean age 53.5 years, 18.8% with comorbid obstructive sleep apnea, 91.3% transitioned from a different medication) showed a mean improvement in ISI score of 7.0 \u00b1 0.54 points (SEM) (p &lt; 0.0001) from 18.0 to 11.0. Overall, 78% of the cohort demonstrated a clinically meaningful improvement as defined by at least a six-point drop in ISI. Total sleep time increased by 54 \u00b1 1.0 min (SEM) (p &lt; 0.0001) from 6.0 h to 6.9 h. Mean sleep latency decreased by 23.9 \u00b1 2.4 min (SEM) (p &lt; 0.0001) from 58.8 min to 34.9 min. Wake after sleep onset decreased by 31.6 \u00b1 3.2 min (SEM) (p &lt; 0.001) from 42.8 min to 11.3 min. Sleep efficiency improved by 10.5 \u00b1 1.1% (SEM) (p &lt; 0.0001) from 79.3% to 89.8%. No significant adverse events were noted during the study duration. Keeping in mind this study\u2019s limitations, these data suggest that for insomnia patients with an incomplete response to current therapy, switching to daridorexant is safe and may be an effective alternative treatment.<\/jats:p>","DOI":"10.3390\/jcm12093240","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T12:10:03Z","timestamp":1682943003000},"page":"3240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Use of Daridorexant among Patients with Chronic Insomnia: A Retrospective Observational Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-3824","authenticated-orcid":false,"given":"Scott G.","family":"Williams","sequence":"first","affiliation":[{"name":"Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA"},{"name":"Departments of Medicine and Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6493-447X","authenticated-orcid":false,"given":"Domingo","family":"Rodriguez-Cu\u00e9","sequence":"additional","affiliation":[{"name":"SleepCues PA, 5603 Duraleigh Rd, Suite 105, Raleigh, NC 27612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"ref_1","unstructured":"American Academy of Sleep Medicine (2014). The International Classification of Sleep Disorders, American Academy of Sleep Medicine. [3rd ed.]. (ICSD-3)."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Reuben, C., Elgaddal, N., and Black, L.I. (2023, February 02). Sleep Medication Use in Adults Aged 18 and Over: United States, 2020. NCHS Data Brief, no 462. Hyattsville, MD: National Center for Health Statistics, Available online: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db462.pdf.","DOI":"10.15620\/cdc:123013"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1007\/s00018-021-03846-2","article-title":"Electrophysiology of ionotropic GABA receptors","volume":"78","author":"Sallard","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"Fritschy","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002130051030","article-title":"Zaleplon and triazolam in humans: Acute behavioral effects and abuse potential","volume":"145","author":"Rush","year":"1999","journal-title":"Psychopharmacology"},{"key":"ref_7","first-page":"31","article-title":"Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds","volume":"66","author":"Griffiths","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited\u2014Will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.addbeh.2014.04.018","article-title":"Age cohort differences in the nonmedical use of prescription zolpidem: Findings from a nationally representative sample","volume":"39","author":"Schepis","year":"2014","journal-title":"Addict. Behav."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addbeh.2018.06.013","article-title":"Prescription tranquilizer\/sedative misuse prevalence and correlates across age cohorts in the US","volume":"87","author":"Schepis","year":"2018","journal-title":"Addict. Behav."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3949\/ccjm.88a.20031","article-title":"Quetiapine for primary insomnia: Consider the risks","volume":"88","author":"Harabasz","year":"2021","journal-title":"Cleve Clin. J. Med."},{"key":"ref_12","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","volume":"162","author":"Holbrook","year":"2000","journal-title":"CMAJ"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012). American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 60, 616\u2013631.","DOI":"10.1111\/j.1532-5415.2012.03923.x"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/M15-1781","article-title":"Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians","volume":"165","author":"Wilt","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Amari, D.T., Juday, T., Frech, F.H., Wang, W., Wu, Z., Atkins, N., and Wickwire, E.M. (2022). Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03165-6"},{"key":"ref_16","unstructured":"(2023, February 02). FDA Drug Safety Communication: FDA Adds Boxed Warning for Risk of Serious Injuries Caused by Sleepwalking with Certain Prescription Insomnia Medicines, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s11606-019-05030-6","article-title":"Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: A Comparative Safety Study","volume":"34","author":"Lavigne","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/00207454.2020.1773460","article-title":"Challenges and opportunities in insomnia disorder","volume":"131","author":"Roach","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"145928","DOI":"10.1016\/j.brainres.2018.08.031","article-title":"Activation of medial hypothalamic orexin neurons during a Go\/No-Go task","volume":"1731","author":"Freeman","year":"2020","journal-title":"Brain Res."},{"key":"ref_21","unstructured":"Alger, S.E., Stekl, E., Allotey-Addo, S., Klosterman, G., and Balkin, T.J. (2021). The Role of Pharmacological Interventions for Sleep Deprivation and Restriction, Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier."},{"key":"ref_22","unstructured":"Merck Sharp & Dohme (2023, February 02). United States Prescribing Information: BELSOMRA\u00ae (Suvorexant), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204569s000lbledt.pdf."},{"key":"ref_23","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.sleep.2022.01.024","article-title":"Impact of lemborexant treatment on insomnia severity: Analyses from a 12-month study of adults with insomnia disorder","volume":"90","author":"Roth","year":"2022","journal-title":"Sleep Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"A139","DOI":"10.1093\/sleep\/zsab072.347","article-title":"348 Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia","volume":"44","author":"Leger","year":"2021","journal-title":"Sleep"},{"key":"ref_28","first-page":"152","article-title":"Daridorexant, a novel dual orexin receptor antagonist, delivers significant improvement in sleep parameters and daytime function for patients with insomnia disorder","volume":"29","author":"Roth","year":"2020","journal-title":"J. SleepRes."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kunz, D., Dauvilliers, Y., Benes, H., Garc\u00eda-Borreguero, D., Plazzi, G., Seboek Kinter, D., Coloma, P., Rausch, M., Sassi-Sayadi, M., and Thein, S. (CNS Drugs, 2022). Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder, CNS Drugs, Epub ahead of print.","DOI":"10.1016\/j.sleep.2022.05.356"},{"key":"ref_30","unstructured":"Morin, C.M. (1993). Insomnia: Psychological Assessment and Management, Guilford Press."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","article-title":"The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response","volume":"34","author":"Morin","year":"2011","journal-title":"Sleep"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1185\/03007990903167415","article-title":"Interpreting score differences in the Insomnia Severity Index: Using health-related outcomes to define the minimally important difference","volume":"25","author":"Yang","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20503121211037903","DOI":"10.1177\/20503121211037903","article-title":"Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant","volume":"9","author":"Suzuki","year":"2021","journal-title":"SAGE Open Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis","volume":"400","author":"Ostinelli","year":"2022","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: Highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"914","DOI":"10.4088\/JCP.09m05571gry","article-title":"Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: A randomized controlled trial","volume":"72","author":"Fava","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"Yardley","year":"2020","journal-title":"Sleep"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101873","DOI":"10.1016\/j.cpr.2020.101873","article-title":"The efficacy of cognitive and behavior therapies for insomnia on daytime symptoms: A systematic review and network meta-analysis","volume":"80","author":"Benz","year":"2020","journal-title":"Clin. Psychol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jsmc.2022.06.014","article-title":"Hypnotic Discontinuation in Chronic Insomnia","volume":"17","author":"Hintze","year":"2022","journal-title":"Sleep Med. Clin."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/9\/3240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:27:36Z","timestamp":1760124456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/9\/3240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12093240"],"URL":"https:\/\/doi.org\/10.3390\/jcm12093240","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}